Type Segment Analysis: Non-Surgical (Largest Segment) vs Surgical (Fastest-Growing Segment)

The non-surgical segment dominated the crohn's disease therapeutics market with a 67.49% share in 2026, reflecting the central role of medication-based management in controlling symptoms, reducing inflammation, and maintaining disease remission. Non-surgical approaches allow ongoing disease management while helping patients avoid the risks and recovery requirements associated with invasive procedures. Advances in therapeutic strategies and increasing emphasis on individualized treatment plans are supporting continued reliance on pharmacological management. The need for long-term disease control also sustains demand for non-surgical treatment options across different stages of crohn's disease.

Surgical treatment is gaining momentum as healthcare providers address cases involving complications or disease progression that cannot be adequately managed through conservative approaches. Surgical intervention can become necessary when structural complications, obstruction, fistulas, or other severe manifestations affect patient outcomes and quality of life. Greater attention to multidisciplinary disease management and improvements in surgical techniques are supporting the role of operative treatment within comprehensive care pathways. As treatment strategies become more individualized, surgical options are increasingly considered when therapeutic management alone is insufficient.

Route of Administration Segment Analysis: Injectable (Largest Segment) vs Oral (Fastest-Growing Segment)

The injectable segment held the largest share of the crohn's disease therapeutics market in 2026, supported by the use of injectable therapies for patients requiring targeted and sustained disease management. Injectable administration is particularly relevant for therapies designed to address significant inflammatory activity and maintain control in patients requiring advanced treatment approaches. Established clinical use and the effectiveness of biologic and other injectable therapies contribute to strong demand. The importance of maintaining disease control over extended treatment periods further supports the segment's leading position.

Oral administration is gaining traction as patients and healthcare providers increasingly value convenient treatment options that can simplify long-term disease management. Oral therapies can reduce dependence on administration through clinical settings and may offer greater flexibility for patients managing chronic conditions. Continued development of oral treatment approaches is broadening therapeutic choices and supporting patient-centric care models. Convenience, treatment accessibility, and the potential to improve adherence are strengthening demand for oral therapies within crohn's disease management.